ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Nichi-Iko Pharmaceutical Co., Ltd.

Business Summary

Nichi-Iko Pharmaceutical Co., Ltd. develops, manufactures, and markets generic pharmaceutical products. Its products are classified into Prescriptive and General Over-the-Counter (OTC) drugs. These products are used for the treatment of circulatory, digestive, respiratory, central and peripheral nervous systems problems. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue166,592M1,502.25M
Gross Profit33,158M299.00M
Operating income7,221M65.11M
Income before tax8,903M80.28M
Net income6,864M61.89M
EBITDA16,987M153.18M
Diluted EPS114.031.02
Dividends Per Share300.27
Total Assets306,838M2,772.17M
Total liabilities190,511M1,721.19M
Total equity116,323M1,050.93M
Operating cash flow23,811M214.71M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 127,021M 143,513M 149,263M 164,717M 166,592M
Gross Profit 46,876M 53,313M 37,611M 40,803M 33,158M
Operating income 9,619M 12,910M 10,026M 13,200M 7,221M
Income before tax 9,488M 15,359M 5,963M 9,067M 8,903M
Net income 6,592M 11,031M 4,796M 8,069M 6,864M
EBITDA 20,265M 24,200M 17,091M 22,179M 16,987M
Diluted EPS 110.13 184.01 84.08 142.92 114.03
Dividends Per Share 26.60 30 30 30 30
Total Assets 139,834M 161,128M 268,900M 278,364M 306,838M
Total liabilities 65,347M 78,531M 185,725M 190,819M 190,511M
Total equity 74,487M 82,597M 83,171M 87,542M 116,323M
Operating cash flow 21,179M 7,097M -4,076M 18,925M 23,811M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 1,156.24M 1,195.10M 1,378.39M 1,486.18M 1,502.25M
Gross Profit 426.70M 443.96M 347.32M 368.15M 299.00M
Operating income 87.55M 107.50M 92.58M 119.09M 65.11M
Income before tax 86.36M 127.90M 55.06M 81.80M 80.28M
Net income 60.00M 91.86M 44.28M 72.80M 61.89M
EBITDA 184.46M 201.52M 157.82M 200.11M 153.18M
Diluted EPS 1.00 1.53 0.77 1.28 1.02
Dividends Per Share 0.24 0.24 0.27 0.27 0.27
Total Assets 1,166.01M 1,433.58M 2,413.17M 2,617.43M 2,772.17M
Total liabilities 544.89M 698.70M 1,666.74M 1,794.25M 1,721.19M
Total equity 621.11M 734.88M 746.39M 823.14M 1,050.93M
Operating cash flow 192.78M 59.10M -37.64M 170.75M 214.71M

Valuation Measures

Mar 2019
PER12.71
ROA2.34%
ROE6.73%
Operating margin4.33%
Profit margin4.12%

Key executives

  • President & Representative Director: Yuichi Tamura
  • Director, Senior Head-Compliance & Internal Audit: Kenji Akane
  • Director & General Manager-Administration: Noboru Inasaka
  • Director & Managing Executive Officer: Takahiro Yoshikawa
  • Auditor: Yoshihito Sugi

Shareholders

  • TAMURA YUICHI /NICHI IKO PHARMACEUTICAL/ (12.9%)
  • Asset Management One Co., Ltd. (5.0%)
  • Hokuhoku Financial Group, Inc. (4.3%)
  • Nipro Corp. (2.0%)
  • The Vanguard Group, Inc. (1.9%)
  • Sumitomo Mitsui DS Asset Management Co., Ltd. (1.8%)
  • Nomura Asset Management Co., Ltd. (1.7%)
  • Nichi-Iko Pharmaceutical Co., Ltd. (1.4%)
  • Goldman Sachs Asset Management LP (1.4%)
  • Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.2%)

Contact Details

Related Companies

  • Nichi-Iko Pharma Tech Co., Ltd.
  • Elmed Co. Ltd.
  • Nichi Iko Pharmaceutical Trust
  • Nichi-Iko Pharmaceutical Employee Incentive Plan
  • Nichiiko Pharma KK
  • Nichiiko Osaka KK
  • Yakuhan Pharmaceutical Co., Ltd.
  • Sagent Pharmaceuticals, Inc.
  • Kobayashi Pharmaceutical Industries Co. Ltd.
  • Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
  • Oriental Pharmaceutical Co., Ltd.
  • Teikoku Medix Co., Ltd.
  • Japan Galen, Inc.
  • Maruko Pharmaceutical Co. Ltd.
  • Nichiiko Pharmaceutical Employee Stock Pwnership Plan

Competitors

  • Hikma Pharmaceuticals Plc
  • Amphastar Pharmaceuticals Inc
Last Updated on 17 Oct, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media